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Abstract 
Background: We recently demonstrated the effect of gonadotropin-releasing 
hormone agonist (GnRHa) on tissue inflammation, angiogenesis and apoptosis in 
endometriosis, adenomyosis and uterine myoma. Here, we investigated expression of 
GnRH receptors (GnRHR) and effect of GnRHa on the proliferation of cells derived from 
endometria and pathologic lesions of women with these reproductive diseases.  
Methods: Biopsy specimens were collected from pathologic lesions and 
corresponding endometria of 35 women with pelvic endometriosis, 45 women with 
ovarian endometrioma, 35 women with adenomyosis, 56 women with uterine myoma 
during laparoscopy or laparotomy. The gene and protein expressions of GnRHR in 
eutopic/ectopic cells and tissues were examined by reverse transcriptase-polymerase 
chain reaction and immunohistochemistry. The immunoreactivity pattern of GnRHR 
expression in respective tissue was analyzed by quantitative-histogram (Q-H) scores. The 
exogenous effect of GnRHa on cell proliferation was examined by 
5-Bromo-2-deoxyuridine incorporation assay. The Ki-67-immunoreactive cell 
proliferation index was analyzed in biopsy specimens derived from GnRHa-treated and 
-non-treated women.  
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Results: GnRH receptors, type I and type II, mRNAs and GnRHR proteins 
were expressed in eutopic endometria and pathologic lesions derived from women with 
endometriosis, adenomyosis and uterine myoma. GnRHR expression was the highest in 
the menstrual phase when compared with other phases of the menstrual cycle. The 
highest Q-H scores of GnRHR immunoreaction were found in blood-filled opaque red 
lesions than in other peritoneal lesions. The exogenous treatment with GnRHa 
significantly suppressed the proliferation of cells derived from respective endometria and 
pathologic lesions when compared with GnRHa-non-treated cells.  
Conclusion: Local tissue expressions of GnRH receptor were detected in 
endometriosis, adenomyosis and uterine myoma. In addition to hypo-estrogenic effect, 
direct anti-proliferative effect of GnRHa may be involved in the regression of these 
reproductive diseases with consequent remission of clinical symptoms.  
 
Key Words: GnRH receptor / GnRH agonist / cell proliferation / reproductive diseases  
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Introduction 
With the advent of isolation and synthesis of gonadotropin-releasing hormone 
(GnRH) by Schally (1971) in the early 1970s, interest in the clinical application of GnRH 
agonist (GnRHa) has grown.  Now in clinical practice, GnRHa has been used for the 
medical treatment of prostate cancer, precocious puberty, endometriosis, adenomyosis 
and uterine myoma. Traditionally, the effect of GnRHa is mediated by competitive down 
regulation of pituitary GnRH receptors (GnRHR), causing a state of hypo-estrogenemia 
resulting in the resolution of pain symptoms and regression of diseases.  
Endogenous GnRH (GnRH I and GnRH II) as well as exogenous GnRHa have 
been demonstrated to exert anti-proliferative and apoptotic effects on cultured 
endometriotic cells and some cancer cells derived from reproductive organs (Borroni et 
al., 2000; Imai et al., 2000; Tang et al., 2002; Limonta et al., 2003; Morimoto et al., 2005; 
Khan et al., 2009). The response of this hormonal medication to reproductive diseases is 
variable depending on the type of the medication, patients background and GnRH 
receptor-ligand binding affinity for individual cells or tissues (Qayum et al., 1990; 
Limonta et al., 1992; Emons et al., 1993; Borroni et al., 2000). Information regarding 
multiple biological functions of GnRHa in peripheral tissues of women with different 
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reproductive diseases was limited. We recently demonstrated changes in tissue 
inflammation, angiogenesis and apoptosis in endometriosis, adenomyosis and uterine 
myoma after GnRHa treatment (Khan et al., 2010). However, studies on the expression of 
GnRHR in peripheral tissues and direct cell proliferation effect of GnRHa in women with 
these reproductive diseases were not well described.   
Therefore, we investigated three main issues in this study. Firstly, we examined 
gene and protein expression of GnRHR in isolated cells and intact tissues derived from 
women with endometriosis, adenomyosis and uterine myoma. Secondly, we examined 
cell proliferation effect of exogenous GnRHa on cells derived the respective endometria 
and pathologic lesions of women with these reproductive diseases. Thirdly, we 
investigated in vivo pattern of changes in cell proliferation in the endometria and 
pathologic lesions derived from GnRHa-treated and -non-treated women.    
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Material and Methods 
Subjects. The subjects in this study were women of reproductive age. From 
February 2004 to June 2009, biopsy specimens were collected from a total of 30 control 
women, 45 women with ovarian endometrioma, 35 women with adenomyosis and 56 
women with uterine myomas who underwent hysteroscopy, laparoscopy or laparotomy 
during this period. All these women were admitted to our hospital with the complaint of 
abnormal genital bleeding, hypermenorrhoea or anemia with or without associated 
complaint of dysmenorrhea or pelvic pain. A fraction of these study groups had variable 
coexistent lesions of pelvic endometriosis. We also separately studied 35 women with 
biopsy proven pelvic endometriosis. All women with pelvic and ovarian endometriosis, 
adenomyosis and uterine fibroids were diagnosed by ultrasonograghapy and magnetic 
resonance image before operation or by laparoscopy and subsequently confirmed by 
histology. The phases of the menstrual cycle in women without hormonal therapy was 
determined by histological dating of eutopic endometria samples taken simultaneously 
with peritoneal lesions, endometrioma, adenomyoma and nodules.  
The staging and morphological distribution of peritoneal lesions of 
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endometriosis were based on the revised classification of the American Society for 
Reproductive Medicine (r-ASRM) (1997). As we described recently (Khan et al., 2004a), 
peritoneal lesions were categorized according to the color appearance of pelvic 
endometriosis. Biopsy specimens from each of these peritoneal lesions were collected for 
subsequent experimental analysis. All biopsy specimens were collected in accordance 
with the guidelines of the Declaration of Helsinki and with the approval of the Nagasaki 
University Institutional Review Board. An informed consent was obtained from all 
women.   
Biopsy specimens. Biopsy specimens were collected from the cyst wall, 
adenomyotic lesion, myoma nodule, autologous myometria, and respective endometria 
derived from women with endometrioma, adenomyosis and uterine myoma during 
operation. Endometrial samples were collected from all women with and without GnRHa 
therapy. We also collected biopsy samples from the eutopic endometria, ectopic 
endometria and adjacent peritoneum of women with pelvic endometriosis and control 
women. All collected biopsy specimens were prepared for formalin-fixed 
paraffin-embedded tissue blocks for subsequent histopathological and 
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immunohistochemical study.  
Isolation of endometrial cells. Isolation and culture of endometrial stromal 
cells and epithelial cells derived from the eutopic/ectopic endometria of women with 
endometriosis, adenomyosis and uterine myoma were processed as described previously 
(Koga et al., 2001; Khan et al., 2005a, 2005b, 2005c, 2008). Briefly, the tissues were 
minced into small pieces and incubated in DMEM/F-12 containing collagenase type I 
(2.5 mg/ml) (Sigma, St Louis, MO, USA) and deoxyribonuclease I (15 U/ml) (Takara, 
Tokyo, Japan) for 2-3 hours at 37℃. The resultant dispersed endometrial cells were 
separated by filtration through a 60-μm nylon cell strainer (Becton Dickinson and Co., 
Franklin lakes, NJ, USA). Endometrial epithelial glands that remained intact were 
retained by the strainer whereas dispersed stromal cells passed through the strainer into 
the filtrate.  
 Endometrial stromal cells in the filtrate were collected by centrifugation and 
resuspended in phenol-red free DMEM/F-12 containing 10% charcoal-stripped FBS, 100 
U/ml penicillin, 0.1 mg/ml streptomycin, and 0.25 μg/ml amphotericin B (all from 
Sigma). Stromal cells were seeded in a 100-mm culture plate and kept at 37℃ in a 
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humidified 5%CO2-95% air atmosphere. At the first passage, cells were plated at a 
density of 2x10
5
 cells/ml. The cells reached confluence in 2 or 3 days and then were used 
for experiments.  
The chocolate cyst linings of the ovaries were collected as the source of 
endometriotic tissues. Stromal cells from cyst wall were collected according to the 
method described in detail previously (Iwabe et al., 1998). We used stromal cells in a 
monolayer culture after the first passage.     
Endometrial epithelial cells were collected by back washing the strainer with 
DMEM/F-12 containing 10% charcoal-stripped FBS, seeded in a 100-mm plate, and 
incubated at 37℃ for 60 min to allow contaminated stromal cells to attach to the plate 
wall. The non-attached epithelial cells were recovered and cultured in the medium at a 
density of 2x10
5
 cells/ml. The cells, which reached confluence in 2 or 3 days, were used 
for experiments. The purity of stromal and epithelial cell preparation was more than 95%, 
as judged by positive cellular staining for vimentin and cytokeratin, respectively and 
negative cellular staining for CD45 (pan-leukocytes) and VWF (endothelial cells). 
Isolation of smooth muscle cells. Biopsy specimens from each of the 
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adenomyotic lesion and myoma nodule of GnRHa-treated and -non-treated women with 
adenomyosis and uterine myoma were collected and smooth muscle cells were isolated in 
primary culture as described previously (Rossi et al., 1992).  
Briefly, fresh biopsy specimens collected in sterile medium were rinsed with 
PBS to remove blood cells. The tissues were cut into small pieces and digested in 2% 
collagenase (Sigma, St Louis, MO, USA) with DMEM and incubated in a shaking water 
bath at 37℃ for 3-6 hours. Isolated smooth muscle cells were collected by centrifugation 
at 460g for 5-10 minutes, washed several times with DMEM containing 1% 
antibiotic-antimycotic solution (Sigma) and cultures in 75cm2 flask in different aliquots. 
The isolated smooth muscle cells were grown as monolayers in 75cm2 flask at a density 
of 2x105 cells per flask. The cells were maintained in pheno-red free DMEM 
supplemented with charcoal-stripped 10% FBS and 1% antibiotic-antimycotic solution 
for 6 days at 37℃ in a humidified culture atmosphere of 5% CO2-95% air. The purity of 
smooth muscle cells was more than 95%, as judged by positive cellular staining for 
desmin or alpha-smooth muscle actin and negative cellular staining for vimentin, 
cytokeratin, CD45 and VWF. The smooth muscle cells were seeded after the third 
Khan KN et al., Page 11  
passage at 2x104 cells per well in a 96 well culture (Greiner) plate for cell proliferation 
study.   
Gene expression of GnRH receptor. Total RNA was isolated using ISOGEN 
method (Molecular Research Center, Tokyo) according to the manufacturer’s protocol. 
RNA (1μg) was added to reverse the transcription reaction (RT-PCR), and cDNA (1μ
L) was subjected to real-time qPCR using Light Cycler (Roche Diagnostics, Mannheim, 
Germany). All primers and probes and amplification conditions for type I GnRH receptor 
and type II GnRH receptor were designed and described previously (Morimoto et al., 
2005; Koga et al., 2000). Reaction parameters were as follows: For GnRHR, 40 cycles of 
denaturing (95℃, 15 sec), annealing (62℃, 10 sec), and extension (72℃, 12 sec); forβ
-actin, 30 cycles at 95℃ for 10 sec, 60℃ for 10 sec, and 72℃ for 10 sec. All PCR 
conditions were followed by melting curve analysis.  
The gene expression levels of type I GnRH receptor and type II GnRH receptor 
were calculated and normalized by dividing the corresponding values of house keeping 
gene β-actin (GB accession number NM001101). Each PCR product was purified with a 
QIAEX II gel extraction kit (QIAGEN), and their identities were confirmed using an ABI 
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PRISMTM 310 genetic analyzer (Applied Biosystems, Foster city, CA).       
Antibodies used. We performed immunohistochemical studies to investigate the 
immunoreaction of GnRHR in intact tissues. GnRHR (AT2.G7:sc-57176), a mouse 
monoclonal antibody against both type I and type II receptor (1:25 dilution), was used to 
immunolocalize GnRHR expression in tissues (Santa Cruz Biotechnology, Inc. CA). 
Ki-67 (MIB-1, Immunotech, Marseille, France), a mouse monoclonal antibody (1:100) 
was used to immunolocalize proliferating cells in biopsy specimens. Non-immune mouse 
immunoglobulin (Ig) G1 antibody in 1:50 dilution was used as a negative control.  
Immunohistochemistry. The details of immunocytochemical or 
immunohistochemical staining were described elsewhere (Khan et al., 2003, 2004b, 
2008; Ishimaru et al., 2004). We used at least two biopsies per patient and three slides per 
biopsy for immunohistochemical analysis.   
The immunoreactivity of GnRHR in biopsy specimens was quantified by a 
modified method of quantitative-histogram score (Q-H score) as described recently 
(Khan et al., 2003, 2005c; Ishimaru et al., 2004). The Q-H score was calculated using the 
following equation: Q-H score=ΣPi (i+1), where i = 1, 2 or 3 and Pi is the percentage of 
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stained cells for each intensity. The staining intensity was graded as 0 = no, 1 = weak, 2 = 
moderate, and 3 = strong. We calculated the mean Q-H scores of five different fields of 
one section by light microscopy at moderate magnification (x200). The cell proliferation 
index (Ki-67 index) in each tissue section was calculated by measuring the mean 
percentage of Ki-67-positive nuclei among total cells in four different microscopic fields 
(x200).    
Cell proliferation assays. 5-Bromo-2-deoxyuridine (BrdU) labeling and 
detection kit measures cell proliferation by quantitating BrdU incorporated into the newly 
synthesized DNA of replicating cells (Takagi, 1993). The incorporated BrdU can be 
detected by a quantitative cellular enzyme immunoassay (Biotrak, Amersham Pharmacia 
Biotech Ltd., UK) using monoclonal antibodies directed against BrdU. It offers a 
non-radioactive alternative to the [
3
H]-thymidine-based cell proliferation and carries 
equal sensitivity and specificity (Takagi, 1993). We examined the proliferation of 
epithelial cells, stromal cells and smooth muscle cells in response to variable doses 
(10-9M to 10-5M) of GnRH agonist (Leuplin: leuprolide acetate, Takeda, Tokyo, Japan).  
The detail procedure of BrdU incorporation assay was described previously 
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(Khan et al., 2005a, 2005b, 2005c). Briefly, desired cells (endometrial cells and smooth 
muscle cells) were cultured in 96 well microtitre plate (10
4 
cell/well). After a 24hr 
pre-incubation period without serum, respective cells were treated with or without 
GnRHa in a serum free medium and incubated for an additional 24 hours. After that, the 
cells were labeled with 10μM of BrdU (100 μL/well) and incubated for 4 hours at 37℃. 
The cells were fixed and genomic DNA was denatured by adding 200μL/well of 
blocking reagent (1:10) for 30 minutes at room temperature (RT). Peroxidase-labeled 
anti-BrdU antibody (1:100) was added (100μL/well) and incubated for 90 minutes at RT. 
After washing three times, TMB (3,3’5,5’-tetramethylbenzidine) substrate solution was 
added (100μL/well) and incubated for 15 minutes at RT for color appearance and finally 
optical density was measured using a microplate reader at an absorbance of 450 nm. The 
intra-assay and inter-assay coefficients of variation were <10% for this assay.   
The values of BrdU incorporated cells in response to GnRH agonist were 
expressed as the percentage of controls (non-treated cells). The cells treated with BrdU 
diluent (PBS solution) was used as negative control. The absorbance values correlated 
directly to the amount of DNA synthesis and to the number of proliferating cells in 
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culture.  
Statistical analysis. All results are expressed as either mean ± SEM or median 
and inter-quartile range (IQR). The clinical characteristics of the subjects were compared 
with one-way analysis of variance and the X
2
 test for any difference between two groups. 
Mann-Whitney U-test or Student’s t-test was used to analyze any difference in cell 
proliferations or protein expressions between two groups. For comparisons among groups, 
the Kruskal-Wallis test was used. A value of p<0.05 was considered to be statistically 
significant.  
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Results 
The clinical features of women with ovarian endometrioma, adenomyosis and 
uterine myoma between GnRHa-treated group and GnRHa-non-treated group and of 
women with pelvic endometriosis and control women are shown in Table 1. The duration 
of GnRHa therapy was also comparable among these three study groups, 4-6 months for 
women with ovarian endometrioma, 3-6 months each for women with adenomyosis and 
uterine myoma. Ten women with ovarian endometriosis, ten with adenomyosis, and eight 
with uterine myoma had coexisting peritoneal lesions.    
Gene expression of GnRH receptor in endometriosis, adenomyosis and 
uterine myoma. As shown in Figure 1, standard RT-PCR analysis demonstrated 
amplified products of type I GnRH receptor and type II GnRH receptor in the eutopic 
endometria of control women and pelvic endometriosis as well as in cultured 
endometriotic epithelial cells and stromal cells (Figure 1, A). Both type I and type II 
GnRHR were also detected in tissues derived from cyst wall, adenomyotic tissue, myoma 
nodule and their corresponding eutopic endometria (Figure 1, B).  Each PCR product was 
sequenced and confirmed to be identical to the sequence of type I GnRH receptor (Chi et 
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al., 1993) and type II GnRH receptor (Grundker et al., 2002). The relative gene levels of 
GnRHR in the eutopic and ectopic endometria are shown in Table 2. An almost similar 
level of GnRHR gene expression was observed in all studied cells and tissues.   
Immunoexpression of GnRHR based on menstrual cycle and r-ASRM 
staging. The immunostaining of GnRHR was found to be weak during the proliferative 
phase (Figure 2A, upper column), moderate during the secretory phase (Figure 2A, 
middle column) and strong during the menstrual phase (Figure 2A, lower column). The 
immunoreactivity of GnRHR as measured by Q-H scores also showed the similar results 
(Figure 2B). The tissue localization of GnRHR was found in both gland cells and stromal 
cells. Comparing to control samples, GnRHR expression was found to be higher in 
samples derived from the secretory phase or menstrual phases of women with 
endometriosis (Figure 2B). We did not find any significant difference of GnRHR 
expression between samples derived from 35 women with stage I-II endometriosis and 25 
women with stage III-IV endometriosis (Figure 2, A and B). We also found GnRHR 
expression in the endometria, pathologic lesions and myometria derived from women 
with endometrioma, adenomyosis and uterine myoma (data not shown).  
Khan KN et al., Page 18  
Immunoexpression of GnRHR in peritoneal lesions and adjacent peritoneum. 
When we distributed immunoexpression of GnRHR in different peritoneal lesions and 
their adjacent peritoneum of pelvic endometriosis, we found a significantly stronger 
immunoreaction and higher Q-H scores of GnRHR expression in the blood- filled opaque 
red lesions and their adjacent peritoneum (p<0.05 for both) when compared with that in 
non-opaque red lesions, black + white lesions and their adjacent peritoneum (Figure 3, A 
and B).  
Immunoexpression of GnRHR in GnRHa-treated and -non-treated samples. 
As shown in Figure 4, we did not find any significant difference in GnRHR 
immunoexpression and Q-H scores in the endometria (upper column), cyst wall (middle 
column) and coexisting peritoneal lesions (lower column) between GnRHa-treated and 
GnRHa-non-treated samples derived from women with ovarian endometrioma (Figure 4, 
A and B). We also found an insignificant difference in the expression of GnRHR in 
GnRHa-treated samples when compared with that of non-treated samples derived from 
women with adenomyosis and uterine myoma (data not shown).        
Effect of GnRHa on the proliferation of endometrial cells. After an initial 
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time-dependent study from day 1 to day 3, we found significant inhibitory response of 
GnRHa on cell proliferation from day 2 to day 3 without any variation among these days. 
Therefore, all the following dose-dependent studies were performed with an incubation 
period of 48 hours.  We examined direct cell proliferation effect of a variable dose of 
GnRHa on epithelial cells and stromal cells derived from the endometria of 25 women 
with ovarian endometrioma, 20 women with adenomyosis and 36 women with uterine 
myoma. All these women had no GnRHa treatment before surgery.  





caused a significant and a dose-dependent inhibition of BrdU incorporation into DNA of 
endometrial epithelial cells and stromal cells derived from women with ovarian 
endometrioma (A), adenomyosis (B) and uterine myoma (C). The maximal 
anti-proliferative effect (30-32% decrease below the control) was observed at 10
-6
 M and 
10
-5 
M concentration of leuprolide acetate.    





M) to higher doses (10
-7
 M to 10
-5 
M) into endometrial cells derived from 
women with endometrioma and uterine myoma (Figure 5, A and C), GnRHa was able to 
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inhibit BrdU incorporation in response to only higher doses (10
-6
 M and 10
-5 
M) into 
endometrial cells derived from women with adenomyosis (Figure 5, B). We could 
exclude the cytotoxic effect of GnRHa on endometrial cells by trypan blue exclusion test. 
In all experiments, spontaneously detached and dead cells were not different between 
GnRHa-non-treated   and GnRHa-treated cells (data not shown).  
Effect of GnRHa on the proliferation of cells derived from pathologic lesions 
of women with endometrioma, adenomyosis and uterine myoma. We examined direct 
cell proliferation effect of GnRHa on cyst wall stromal cells derived from women with 
ovarian endometrioma and on smooth muscle cells derived from each of adenomyotic 
lesions and myoma nodules (Figure 6).  
We found that GnRHa (leuprolide acetate) was able to significantly suppress 
BrdU incorporation into cyst wall stromal cells at a dose of 10-7 M to 10-5 M (Figure 6A, 
p<0.05 vs. non-treated cells), into smooth muscle cells derived from adenomyotic lesions 
at a dose of 10-6 M and 10-5 M (Figure 6B, p<0.05 vs. non-treated cells), and into smooth 
muscle cells derived from myoma nodules at a dose of 10-8M to 10-5M (Figure 6C, p<0.05 
vs. non-treated cells).  
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We did not find any significant anti-proliferative effect of GnRHa (leuprolide 
acetate) on cells derived from both endometria (data not shown) and pathologic lesions in 
8/25 (32%) of women with endometrioma, in 6/20 (30%) of women with adenomyosis, 
and in 10/36 (28%) of women with uterine myoma (Figure 7).  
Effect of GnRHa on the proliferation of cells derived from the eutopic and 
ectopic endometria of women with pelvic endometriosis. In addition to its effect on cells 
derived from the endometria and pathologic lesions of women with ovarian 
endometrioma, adenomyosis and uterine myoma, we also found that GnRHa retains its 
direct cell proliferation effect on cells derived from women with pelvic endometriosis.  
As shown in Figure 8, GnRHa was able to significantly suppress BrdU 
incorporation into epithelial cells and stromal cells derived from the eutopic endometria 
(A) and ectopic endometria (B) of women with pelvic endometriosis. The direct 
anti-proliferative effect of GnRHa on eutopic and ectopic endometrial cells was observed 
from a lower dose to high dose (10-8 M to 10-5 M) (Figure 8, A and B). We did not find 
any significant anti-proliferative effect of GnRHa on cells derived from 8/35 (23%) of 
women with pelvic endometriosis (data not shown).  
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    Immunoexpression of Ki-67 in endometria and pathologic lesions. In order 
to examine the cell proliferation effect of GnRHa in intact tissue, we investigated 
immunoreaction of Ki-67, a cell proliferation marker, in GnRHa-treated and -non-treated 
biopsy specimens derived from the endometria and respective pathologic lesions of 
women with ovarian endometrioma, adenomyosis and uterine myoma.  
Figure 9 shows the tissue localization of Ki-67 in the endometria and 
pathologic lesions of GnRHa-treated and -non-treated biopsy specimens derived from 
women with ovarian endometrioma (A), adenomyosis (B) and uterine myoma (C). We 
found that Ki-67 index was significantly lower in both endometria (Figure 10, A) and 
pathologic lesions (Figure 10, B) of GnRHa-treated samples derived from women with 
endometrioma, adenomyosis and uterine myoma when compared with the corresponding 
Ki-67 index in GnRHa-non-treated samples derived from these three groups of women. 
Although data not shown, we also found a similarly decreased pattern of Ki-67 index in 
the GnRHa-treated myometria derived from women with adenomyosis and uterine 
myoma. 
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Discussion 
Although a few previous literatures demonstrated the anti-proliferative effect 
of exogenous GnRH agonist or endogenous GnRH II on endometrial cells derived from 
women with endometriosis (Borroni et al., 2000; Morimoto et al., 2005), we further 
demonstrated the direct anti-proliferative effect of GnRHa on the cells derived from 
endometria and pathologic lesions of four groups of women such as women with ovarian 
endometriosis, pelvic endometriosis, adenomyosis and uterine myoma. Based on the 
limited information on the presence of GnRHR expression in peripheral tissues, we could 
detect both gene and protein expression of GnRHR in cells and tissues derived from these 
women.  
We found that exogenous treatment with a variable concentration of GnRHa 
was able to significantly suppress the proliferation of cells derived from the endometria 
and pathologic lesions of women not only with endometriosis but also of women with 
adenomyosis and uterine myoma. These direct anti-proliferative effects of GnRHa in 
vitro correspond to in vivo results of Ki-67, a cell proliferation marker, in intact tissues. In 
fact, Ki-67 index was significantly lower in both endometria and pathologic lesions 
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derived from GnRHa-treated women than from GnRHa-non-treated women. Although 
we could not exclude the hypo-estrogenic effect of GnRHa on the changes in Ki-67 index, 
our in vitro cell proliferation study confirmed direct anti-proliferative effect of GnRHa on 
pathologic lesions.   
Additional interesting findings of our current study are that both eutopic and 
ectopic endometrial cells derived from women with pelvic endometriosis equally express 
GnRHR in both gene and protein level and GnRHa also retains its direct anti-proliferation 
effect on both eutopic and ectoipic endometrial cells derived from women with pelvic 
endometriosis. This indicates that when women with ovarian endometrioma, 
adenomyoma and uterine myoma are treated with GnRHa, this estrogen suppressing 
agent is equally effective in reducing the growth of peritoneal lesions coexisting with 
these reproductive diseases.  
Although we did not find any significant difference in GnRHR protein 
expression between early (stage I-II) and advanced endometriosis (stage III-IV), we 
found an increased transition of GnRHR expression among different phases of the 
menstrual cycle. Our results are in consistent with the previous results that demonstrated 
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protein expression of GnRHR throughout all phases of menstrual cycle with a significant 
increase in the secretory phase when compared with the proliferative phase (Casañ et al., 
1998; Raga et al., 1998). Again, we did not find any significant difference in GnRHR 
protein expression in biopsy samples between GnRHa-treated and GnRHa-non-treated 
women with endometrioma, adenomyosis and uterine myoma. This indicates that unlike 
central pituitary action, the anti-proliferative effect of GnRHa on each cell type may not 
depend on the down-regulation of GnRHR rather on the amount and binding affinity of 
GnRHa for its receptor in peripheral tissues. Further studies are needed to clarify our 
current findings.   
We also found higher immunoexpression of GnRHR in the blood-filled opaque 
red lesions and their adjacent peritoneum than in non-opaque or other less active 
peritoneal lesions and their adjacent peritoneum derived from women with pelvic 
endometriosis. This could be due to increased production of different pro-inflammatory 
cytokines and growth factors by opaque red lesions than by other peritoneal lesions (Khan 
et al., 2004a). These results are biologically significant. GnRHa treatment may not only 
suppress the growth of peritoneal lesions coexisting with these reproductive diseases, this 
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treatment may also reduce blood loss or inflammatory reaction in pelvic environment. In 
fact, we recently demonstrated that GnRHa was able to suppress inflammatory response, 
angiogenic response and induce apoptosis in women with endometriosis, adenomyosis 
and uterine myoma (Khan et al., 2010).  
    One important finding of our current study is that exogenous treatment with 
similar doses of GnRHa did not affect cell growth in 23 % of women with pelvic 
endometriosis, 32% of women with endometrioma, 30% of women with adenomyosis, 
and 28% of women with uterine myoma regardless of the expression of GnRHR. Our 
results are supported by the study of Borroni et al. (2000) who also found no 
anti-proliferative effect of GnRHa (leuprolide acetate) on endometriotic cells derived 
from 60% of cases with ovarian endometriosis. In addition, we found a differential 
cellular response of GnRHa in different diseases, more in cells from endometriosis and 
myoma and less in cells from adenomyosis. This cellular variation in growth inhibition in 
response to GnRHa treatment can be explained by a difference in cellular histogenesis or 
a difference in GnRH receptor-ligand binding affinity in cells derived from women with 
different reproductive diseases. In fact, previous studies investigating the presence of 
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GnRH receptor in different tissues revealed the presence of high affinity/low capacity and 
low affinity/high capacity binding sites (Qayum et al., 1990; Limonta et al., 1992; Emons 
et al., 1993) that may coexist in the same tissue.  
Leuprolide acetate, the type of GnRHa, as we used in our current study, has 
been found to interact with type I GnRH receptor, where type II GnRH receptor functions 
as a co-receptor (Borroni et al., 2000; Imai et al., 2000). In our present study, 
concentrations of GnRHa used are within the pharmacological range in the peripheral 
circulation. In human, serum leuprolide acetate concentration after subcutaneous 
infection of 1.88 mg and 3.75 mg may range from 10
-8
 M to 10
-7
 M and 0.5x10
-6
 M to 
10
-5
 M, respectively, over a five-week period (Mazzei et al., 1990). Thus, theoretically, 
this compound may affect endometrial cell proliferation also in vivo.     
 Finally we conclude that in addition to ovarian endometriosis, peripheral 
tissues derived from women with pelvic endometriosis, adenomyosis, and uterine myoma 
equally express GnRHR at the gene and protein level. In addition to hypo-estrogenic 
effect and other multifunctional roles of GnRHa in peripheral tissues as we described 
recently (Khan et al., 2010), GnRHa may also exert direct anti-proliferative effect on 
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different cells derived from women with these reproductive diseases. All these biological 
functions of GnRHa may be involved in the regression of these diseases with consequent 
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Figure legends 
Figure 1. Standard RT-PCR analysis of the expression of type I GnRH receptor and type 
II GnRH receptor mRNA in the eutopic endometrial tissues of control woman (lane 1), 
woman with pelvic endometriosis (lane 2), isolated epithelial cells (lane 3) and stromal 
cells (lane 4) are shown in the upper panel (A). The lower panel (B) shows the mRNA 
expression of type I and type II GnRH receptor in the eutopic endometrium (lane 1) and 
cyst wall (lane 2) of woman with endometrioma, in the eutopic endometrium (lane 3) and 
adenomyotic tissues (lane 4) of woman with adenomyosis, in the eutopic endometrium 
(lane 5) and nodule (lane 6) of woman with uterine myoma. The PCR products show the 
predicted sizes on the basis of cDNA sequence. M represents molecular marker; RT (-) 
indicates negative control with no reverse transcription. PCR band of each lane is the 
representative of six different samples with similar results.    
 
Figure 2. Shows immunohistochemical staining of GnRHR (A) and 
quantitative-histogram (Q-H) scores of GnRHR immunoreactivity (B) in eutopic 
endometrial tissues derived from 30 control women, 35 women with pelvic endometriosis 
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and 25 women with ovarian endometriosis based on phases of menstrual cycle and 
r-ASRM staging of endometriosis. Kruskal-Wallis test indicated that Q-H scores of 
GnRHR were the highest in the menstrual phase, intermediate in the secretory phase and 
lowest in the proliferative phase (B). No significant difference was observed in the Q-H 
scores of GnRHR expression between stage I-II endometriosis (hatched bar) and stage 
III-IV endometriosis (black bar) (B). Boxes represent the distance (interquartile range) 
between the first (25%) and third (75%) quartiles, and horizontal lines in the boxes 
represent median values.  
 
Figure 3. Shows immunohistochemical staining of GnRHR (A) and 
quantitative-histogram (Q-H) scores of GnRHR immunoreactivity (B) in different 
peritoneal lesions (white bar) based on color appearance and their adjacent peritoneum 
(black bar) derived from 35 women with pelvic endometriosis. The left column of upper 
Figure (A) shows H-E staining of respective peritoneal lesions, middle column shows 
immunostaining of GnRHR in peritoneal lesions, and right column shows 
immunostaining of GnRHR in adjacent peritoneum of respective peritoneal lesions. The 
Khan KN et al., Page 37  
Q-H scores of GnRHR expression were significantly higher in the blood-filled opaque 
red lesions and their adjacent peritoneum (*p<0.05 for each) when compared with that in 
non-opaque red lesions or black + white lesions. Boxes represent the distance 
(interquartile range) between the first (25%) and third (75%) quartiles, and horizontal 
lines in the boxes represent median values. 
 
Figure 4. Shows immunohistochemical staining of GnRHR (A) and 
quantitative-histogram (Q-H) scores of GnRHR immunoreactivity (B) in GnRHa-treated 
(right column, A) and -non-treated (left column, A) endometria (upper column), cyst wall 
(middle column) and coexisting peritoneal lesions (lower column) derived from women 
with ovarian endometrioma. Nonimmune mouse IgG-stained slides are shown against 
each specimen. We did not find any significant difference in the Q-H scores of GnRHR 
expression in samples between GnRHa-non-treated (n=25) (white bar) and 
GnRHa-treated (n=20) (black bar) women with endometrioma (B). Boxes represent the 
distance (interquartile range) between the first (25%) and third (75%) quartiles, and 
horizontal lines in the boxes represent median values. 
Khan KN et al., Page 38  
Figure 5. Shows effects of GnRHa (leuprorelin acetate) on BrdU incorporation into 
epithelial cells (black bar) and stromal cells (open bar) derived from the eutopic 
endometria of women with ovarian endometrioma (A), adenomyosis (B) and uterine 
myoma (C). Both GnRHa-treated and -non-treated endometrial epithelial cells and 
stromal cells were incubated for 48hr. Results are shown as the mean percentage of the 
untreated cells (± SEM) of triplicate experiments using cells derived from different 
women who were responsive to GnRHa. Back and white bar at far right indicate negative 
control of cells treated with BrdU diluent. *p<0.05 vs. non-treated cells for A, B, and C.   
 
Figure 6. Shows effects of GnRHa (leuprorelin acetate) on BrdU incorporation into 
stromal cells (A) derived from cyst wall of women with ovarian endometrioma and 
smooth muscle cells derived from the pathologic lesions of women with adenomyosis (B) 
and uterine myoma (C). Cyst wall stromal cells and respective smooth muscle cells were 
treated with GnRHa at the indicated concentration for 48hr. Results are shown as the 
mean percentage of the untreated cells (± SEM) of triplicate experiments using cells 
derived from different women who were responsive to GnRHa. White bar indicates 
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negative control of cells treated with BrdU diluent. *p<0.05 vs. non-treated cells for A, B, 
and C.  
 
Figure 7. Shows effects of GnRHa (leuprorelin acetate) on BrdU incorporation into 
stromal cells (A) derived from cyst wall of eight women with ovarian endometrioma and 
smooth muscle cells derived from the pathologic lesions of six women with adenomyosis 
(B) and 10 women with uterine myoma (C) who were resistant to the effect of GnRHa. 
We did not find any difference in BrdU incorporation into each of these cells at the 
indicated dose of GnRHa. Results are shown as the mean percentage of the untreated cells 
(± SEM) of triplicate experiments using cells derived from these three groups of women. 
White bar indicates negative control of cells treated with BrdU diluent.   
 
Figure 8. Shows effects of GnRHa (leuprorelin acetate) on BrdU incorporation into 
epithelial cells (black bar) and stromal cells (open bar) derived from the eutopic 
endometria (A) and ectopic endometria (B) of 35 women with pelvic endometriosis. Both 
GnRHa-treated and non-treated epithelial cells and stromal cells were incubated for 48hr. 
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Results are shown as the mean percentage of the untreated cells (± SEM) of triplicate 
experiments using cells derived from women who were responsive to GnRHa.. *p<0.05 
vs. non-treated cells for A and B.  
 
 Figure 9. Shows immunohistochemical staining of Ki-67, a cell proliferation marker, in 
the GnRHa-non-treated (upper column, A, B and C) and GnRHa-treated (lower column, 
A, B and C) endometria and pathologic lesions derived from women with ovarian 
endometrioma (upper left block, A), adenomyosis (upper right block, B) and uterine 
myoma (lower block, C). GnRHa (-), GnRHa-non-treated samples; GnRHa (+), 
GnRHa-treated samples.  
 
Figure 10. Shows Ki-67 index (percentage of Ki-67 immunoreactive cells among total 
cells) in the biopsy specimens derived from the endometria (A) and pathologic lesions (B) 
of GnRHa-non-treated (white box) and GnRHa-treated (hatched box) women with 
ovarian endometrioma, adenomyosis and uterine myoma. The Ki-67 indices were found 
to be significantly lower in the GnRHa-treated samples when compared with that in 
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GnRHa-non-treated samples (p<0.05 for each). Boxes represent the distance 
(interquartile range) between the first (25%) and third (75%) quartiles, and horizontal 
lines in the boxes represent median values. 
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